Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials
POSTS IN CATEGORY
Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials
Successful performance of plasma compression prototype confirms path to commercialization General Fusion’s plasma compression prototype
BEIJING and LONDON and PARIS and SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) — After
CHIPPENHAM, United Kingdom, Jan. 10, 2022 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX:
Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test
Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial
The Minister of Health also shared that since the Early Endemic Phase began on the
44 new COVID-19 cases were confirmed yesterday bringing the total number of cases to 15,678.
Copyright 2024 © bruneitribune.com All rights Reserved.